Displaying 6 results:

Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19

Xiangyang Xie, Yuanliang Jiang, Yuan Zeng, Hui Liu

Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system

Michael A Jarvis, Frederick A Hansen, Kyle Rosenke, Elaine Haddock, Christopher Rollinson, Simon Rule, Graham Sewell, Andrew Hughes, Heinz Feldmann

Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B

Boris JB Beudeker, Zwier MA Groothuismink, Robert A de Man, Harry LA Janssen, Annemiek A van der Eijk, Andre Boonstra, Milan J Sonneveld

Dynamics of HBV surface antigen related end points in chronic hepatitis B infection: a systematic review and meta-analysis

Yusi Chen, Justin Jinhui Li, Rong Chen, Gailing Li, Jia Ji

DAA-based treatment for HIV–HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study

Loredana Alessio, Lorenzo Onorato, Vincenzo Sangiovanni, Francesco Borrelli, Elio Manzillo, Vincenzo Esposito, Filomena Simeone, Salvatore Martini, Nicolina Capoluongo, Sebastiano Leone, Giovanni Di Filippo, Maurizio D’Abbraccio, Lucia Aprea, Angelo Salomone Megna, Eugenio Milano, Viviana Rizzo, Annalisa Saracino, Nicola Coppola

The effects of nucleoside/nucleotide analogues on host immune cells: the baseline for future immune therapy for HBV?

Lauke L Boeijen, Michelle Spaan, André Boonstra